ImmunoBiochem recently announced a multi-target license and option agreement with ImmunoGen to advance novel, first-in-class antibody drug conjugates. The collaboration will combine ImmunoGen's proprietary linker and payload technologies with ImmunoBiochem's antibodies directed against specific targets.
ImmunoBiochem is an alumnus of the CAAP® program and presented at the OBIO® Investment Summit.